Charles River Laboratories shares are down about 3.6% in the latest session as investors refocus on the company’s near-term growth profile following its planned divestitures and related restructuring actions. The most recent portfolio update includes agreements to divest the CDMO and Cell Solutions businesses and to sell certain European Discovery Services assets, with closings expected in Q2 2026.

A key overhang is that the planned divestitures are expected to reduce reported 2026 revenue by slightly more than $200 million, which can pressure near-term growth optics even if the moves are intended to improve margins and focus the portfolio. With the transactions not yet closed, the market is also pricing execution risk around timing, final economics (including contingent payments), and how quickly the remaining business can re-accelerate.

Sentiment has also been sensitive to operational changes tied to the strategic pivot, including site actions and workforce reductions, which can amplify concerns about demand visibility across research and manufacturing services. Separately, the company disclosed leadership changes, including a CFO transition and an expanded legal leadership structure, adding another layer of near-term transition risk for investors to monitor.